Eutilex.Co.,Ltd (KOSDAQ:263050)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,933.00
-23.00 (-1.18%)
Feb 18, 2025, 9:00 AM KST
-27.19%
Market Cap 71.86B
Revenue (ttm) 6.89B
Net Income (ttm) -25.34B
Shares Out 36.83M
EPS (ttm) -689.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 93,036
Average Volume 75,127
Open 1,957.00
Previous Close 1,956.00
Day's Range 1,901.00 - 1,975.00
52-Week Range 1,750.00 - 3,700.00
Beta 0.33
RSI 54.69
Earnings Date Mar 21, 2025

About Eutilex.Co.,Ltd

Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies. The company was founded in 2008 and is headquartered in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 263050
Full Company Profile

Financial Performance

In 2023, Eutilex.Co.,Ltd's revenue was 131.65 million, a decrease of -38.95% compared to the previous year's 215.66 million. Losses were -27.72 billion, -17.08% less than in 2022.

Financial Statements

News

There is no news available yet.